Document is current
Any future updates will be listed below
-
Authors
Baldi, Caterina https://orcid.org/0000-0002-3070-5568
Celletti, Eleonora https://orcid.org/0009-0007-5301-9900
Bugatti, Serena https://orcid.org/0000-0002-5396-7077
Govoni, Marcello https://orcid.org/0000-0003-0499-5773
Cazzato, Massimiliano https://orcid.org/0000-0002-9437-8359
Picchianti Diamanti, Andrea https://orcid.org/0000-0002-8552-4641
Fornaro, Marco https://orcid.org/0000-0003-1716-7432
Guggino, Giuliana https://orcid.org/0000-0003-2479-6958
Navarini, Luca https://orcid.org/0000-0001-8537-1510
D’Agostino, Maria Antonietta https://orcid.org/0000-0002-5347-0060
Quartuccio, Luca https://orcid.org/0000-0002-0134-6439
Ciccia, Francesco https://orcid.org/0000-0002-9352-1264
Dagna, Lorenzo https://orcid.org/0000-0002-7428-315X
Stobbione, Paolo https://orcid.org/0009-0005-5687-6647
Triggiani, Massimo https://orcid.org/0000-0001-7318-2093
Viapiana, Ombretta https://orcid.org/0000-0003-1917-5655
Giardina, Annarita https://orcid.org/0000-0001-8414-9643
Moroncini, Gianluca https://orcid.org/0000-0002-0380-0105
Caporali, Roberto https://orcid.org/0000-0001-9300-6169
Bazzani, Chiara https://orcid.org/0000-0002-7710-6693
Tirri, Enrico https://orcid.org/0000-0002-3304-7740
Lomater, Claudia https://orcid.org/0000-0001-6512-941X
Di Fino, Sara https://orcid.org/0009-0000-6651-8070
Morello, Francesca https://orcid.org/0009-0006-1449-8649
Selmi, Carlo https://orcid.org/0000-0002-0323-0376
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04497597 at ClinicalTrials.govDocuments that mention this clinical trial
Achievement and Maintenance of Remission with Upadacitinib in Patients with Moderate-to-Severe Rheumatoid Arthritis in Italy: 1-Year Data from UPHOLD, a Prospective Real-World Observational Study
https://doi.org/10.1007/s40744-026-00845-2
Achievement and Maintenance of Disease Targets with Upadacitinib in Rheumatoid Arthritis: 2-Year Outcomes from the UPHOLD Real-World Study
https://doi.org/10.1007/s40744-026-00826-5
AB0200 IMPROVEMENT OF SLEEP IMPAIRMENT IN PATIENTS WITH RHEUMATOID ARTHRITIS ACHIEVING REMISSION OR PAIN RELIEVE WITH UPADACITINIB: RESULTS FROM THE POST-MARKETING OBSERVATIONAL SLEERA STUDY
https://doi.org/10.1136/annrheumdis-2023-eular.3146
POS0653 ACHIEVEMENT AND MAINTENANCE OF REMISSION WITH UPADACITINIB IN PATIENTS WITH MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS IN A REAL-WORLD SETTING: 1-YEAR OUTCOMES FROM THE UPHOLD STUDY
https://doi.org/10.1136/annrheumdis-2024-eular.2238
-
Funding
Funding for this research was provided by:
AbbVie
- License Information
-
More Information
Article History
Received: 16 December 2025
Accepted: 12 March 2026
First Online: 12 April 2026
Declarations
:
: Sara Di Fino and Francesca Morello are AbbVie employees and may own AbbVie stocks/options. Caterina Baldi declares having collaborated with AbbVie and Lilly. Serena Bugatti received speaking fees from AbbVie, Alfasigma, Fresenius Kabi, Lilly, Novartis, UCB. Marcello Govoni received speaking fees from AbbVie, Eli Lilly, Alfasigma, GSK, Pfizer, AstraZeneca and research grant from Eli Lilly and AbbVie. Massimiliano Cazzato declares having collaborated with the following companies: AbbVie, Lilly and UCB. Andrea Picchianti Diamanti received speaking fees from AbbVie, Johnson & Johnson, AstraZeneca, GSK, Novartis, UCB and research grants from AbbVie and Pfizer. Marco Fornaro received speaking fees from AbbVie, GSK, Lilly and Boehringer Ingelheim. Giuliana Guggino received speaking fees from AbbVie, Alfasigma, Lilly, Novartis, UCB, GSK. Luca Navarini received speaking fees from AbbVie, Janssen, Novartis, Celgene, BMS, Galapagos, Italfarmaco, Eli Lilly, Roche, UCB. Maria Antonietta D’Agostino received speaking fees from AbbVie, Alfasigma, Amgen, AstraZeneca, BMS, Eli Lilly, GSK, J&J, MSD, Novartis, Pfizer, UCB; consultancies with Eli Lilly, J&J, MSD, Novartis, UCB. Grants: Pfizer, Novartis, AbbVie, AstraZeneca, UCB, Alfasigma. Luca Quartuccio received speaking fees from AbbVie, Johnson & Johnson, AstraZeneca, GSK, CSL Vifor, and research grant from Roche, AbbVie, Pfizer. Francesco Ciccia received speaking fees from AbbVie, Alfasigma, Amgen, AstraZeneca, BMS, Eli Lilly, GSK, J&J, Novartis, Otsuka, Pfizer, UCB; consultancies with Eli Lilly, J&J, Novartis, UCB. Grants: Pfizer, Novartis. Lorenzo Dagna: received consultation honoraria from AbbVie, Alfasigma, Amgen, AstraZeneca, Biogen, Eli Lilly, Galapagos, GSK, Johnson & Johnson, Kiniksa Pharmaceuticals, Merck Sharp & Dohme, Novartis, Sanofi, SOBI, UCB and Vifor. Ombretta Viapiana received speaker and consultant fees from Eli Lilly, AbbVie, Angelini, Grunenthal, Amgen, UCB, Fresenius Kabi. Gianluca Moroncini received research grants from AbbVie. Roberto Felice Caporali received speaker honoraria from AbbVie, Lilly, Alfasigma, Pfizer, Novartis, UCB, J&J. Chiara Bazzani received speaking fees from AbbVie, Novartis, UCB. Claudia Lomater: declares no conflicts of interest. Carlo Selmi: Consulting/speakers fee (AbbVie, Amgen, Alfasigma, Biogen, Eli-Lilly, Recordati Rare Diseases, Johnson & Johnson, Novartis, Octapharma, Pfizer, Recordati Rare Disease, SOBI, UCB); Research support (AbbVie, Amgen, Johnson and Johnson, Novartis, Pfizer) Paolo Stobbione, Eleonora Celletti, Massimo Triggiani, Annarita Giardina, Enrico Tirri declare that they have no conflicts of interest.
: This study adhered to STROBE guidelines [ ] and was conducted according to International Council for Harmonisation standards, local regulations, and the Declaration of Helsinki. All participants provided written informed consent, and the protocol was approved by institutional review boards or ethics committees at each study site (Prof. Carlo Selmi; Ethics Committee, Humanitas; Milan Italy on 30/04/2021; protocol number: CE HUMANITAS ex D.M. 8/2/2013 346/21).
